Skip to Content

Cancer Imaging Program

  1. Contact Us

Research & Funding

Past CIP InitiativesRSS

This page lists past opportunities from CIP.

Requests for Application (RFA) are usually announced with special application dates; there is no possibility for applying after that date. Program Announcements (PA, PAR) may be open for a set period of time, such as 3 years or less; applications submitted in response to Program Announcements may be due on the standard dates (February 1, June1, and October 1) or may have special dates for receipt of applications. Please pay attention to these dates. Contact a CIP staff member if you have questions.

  • PA-06-398: Novel Technologies For In Vivo Imaging (R21/R133)

    This Program Announcement (PA) replaces PA-04-095.

    Through this Funding Opportunity Announcement (FOA), the National Cancer Institute (NCI) solicits Phased Innovation (R21/R33) grant applications from applicant organizations that propose the development and delivery of novel image acquisition or enhancement technologies and methods for biomedical imaging and image-guided interventions and therapy, and which may incorporate limited pilot or clinical feasibility evaluations using either pre-clinical models or clinical studies. This FOA is primarily intended to facilitate the proof-of-feasibility, development, and delivery of novel imaging technologies for early detection, screening, diagnosis, image-guided interventions, and treatment of various diseases, and, secondarily, to facilitate limited evaluation studies to show proof-of-concept and functionality.

    See full description in NIH Guide:PA-06-398

    What is the R21 grant mechanism?
    What is the R33 grant mechanism?

  • PA-06-399: Novel Technologies For In Vivo Imaging (R33)

    This Program Announcement (PA) replaces PA-04-095.

    Through this Funding Opportunity Announcement (FOA), the National Cancer Institute (NCI) solicits R33 (Phase II, Developmental) grant applications from applicant organizations that propose the development and delivery of novel image acquisition or enhancement technologies and methods for biomedical imaging and image-guided interventions and therapy, and which may incorporate limited pilot or clinical feasibility evaluations using either pre-clinical models or clinical studies. This FOA is primarily intended to facilitate the development and delivery of novel imaging technologies for early detection, screening, diagnosis, image-guided interventions, and/or treatment of various diseases.

    See full description in NIH Guide:PA-06-399

    What is the R33 grant mechanism?

  • PA-06-371: In Vivo Cancer Imaging Exploratory/Developmental Grants (R21)

    • Release Date: April 27, 2006
    • Application Receipt Date: standard dates
    • Contacts:

      Anne E. Menkens, Ph.D. (am187k@nih.gov) at 301-435-9024

    The Cancer Imaging Program (CIP) of the Division of Cancer Treatment and Diagnosis (DCTD) solicits exploratory/developmental (R21) applications that articulate exploratory/developmental research focused on in vivo cancer imaging. The R21 mechanism will provide investigators at all career levels with a defined level of funding adequate for the initial development and/or feasibility testing of high impact concepts. Topics considered responsive to this Program Announcement will cover the entire spectrum of in vivo cancer imaging research, from basic discovery of new cancer imaging agents and technologies, through pre-clinical testing and validation, to the early feasibility testing of those novel agents and technologies in small clinical trials. The applicant may request a project period of up to two years with a combined budget for direct costs of up $275,000 for the two year period.

    • No set-aside

    See full description in NIH Guide:PA-06-371

  • RFA-CA-07-004: Small Animal Imaging Resource Program (U24) (NCI)

    • Release Date: April 10, 2006
    • Application Receipt Date: May 18, 2006
    • Contacts:

      Barbara Croft, Ph.D. (croftb@mail.nih.gov) at 301-435-9025

    • Letter of Intent Receipt Date: April 18, 2006

    The NCI invites applications from extramural investigators for Small Animal Imaging Resources (SAIRs). These grants will support: (a) shared imaging resources to be used by cancer investigators; (b) research related to small animal imaging technology or methodology; and (c) training of both professional and technical support personnel interested in the science and techniques of small animal imaging. Small Animal Imaging Resources (SAIRs) will enhance capabilities for conducting basic, translational, and clinical cancer research relevant to the mission of the NCI. Major goals of this initiative are to increase efficiency, synergy, and innovation of such research and to foster research interactions that cross disciplines, approaches, and levels of analysis. Building and strengthening such links holds great potential for better understanding cancer, and ultimately, for better treatment and prevention. The application implements the new multiple-PI policy.

    See full description in NIH Guide:RFA-CA-07-004

  • PA-06-032: An SBIR Initiative for Image-Guided Cancer Interventions (R43/R44)

    The purpose of this funding opportunity is to support the development and clinical validation of systems for image-guided interventions (IGI) for cancer. Specifically, the goals of this program are to provide support for: the development and optimization of fully integrated cancer imaging, monitoring, and therapy systems; validation of integrated IGI systems through clinical evaluations; the development of multiple prototype integrated IGI systems as required for multi-site clinical evaluations; and partnerships among small business, large business, and academic clinical centers, as well as small business joint ventures, in order to reach the research goals.

    See full description in NIH Guide:PA-06-032

  • PA-06-031: Image-Guided Cancer Interventions (STTR [R41/R42])

    The purpose of this funding opportunity is to support the development and clinical validation of systems for image-guided interventions (IGI) for cancer. Specifically, the goals of this program are to provide support for: the development and optimization of fully integrated cancer imaging, monitoring, and therapy systems; validation of integrated IGI systems through clinical evaluations; the development of multiple prototype integrated IGI systems as required for multi-site clinical evaluations; and partnerships among small business, large business, and academic clinical centers, as well as small business joint ventures, in order to reach the research goals.

    See full description in NIH Guide:PA-06-031

  • NOT-OD-05-060: Small Business Innovation Research Program Request for Proposals

    • Release Date: September 06, 2005
    • Application Receipt Date: November 4, 2005
    • Contacts:

      Barbara Croft, Ph.D., (bc129b@nih.gov) at 301-435-9025
      Anne Menkens, Ph.D., (menkensa@mail.nih.gov) at 301-496-9531

    Small Business Innovation Research Program (NOT-OD-05-060) Request for Proposals

    The purpose of this notice is to (1) announce the issuance of the SOLICITATION OF THE PUBLIC HEALTH SERVICE FOR SMALL BUSINESS INNOVATION RESEARCH CONTRACT PROPOSALS (PHS 2006-1); and (2) inform the public about the opportunities that the SBIR program offers to small business concerns as well as to scientists at research institutions. The National Cancer Institute has announced 21 research topics, among them #207 Synthesis Modules for Radiopharmaceutical Production, #208 Targetry Systems for Production of Research Radionuclides and #223 Synthesis and High-throughput Screening of in vivo Cancer Molecular Imaging Agents. Any small business concern that intends to submit an SBIR contract proposal under this Solicitation should provide the appropriate contracting officer(s) with early, written notice of its intent, giving its name, address, telephone, and topic number(s). If a topic is modified or canceled before this Solicitation closes, only those companies that have expressed such intent will be notified.

    National Cancer Institute (NCI) contracting officer:
    Ms. Mary Landi-O'Leary, Phone: (301) 435-3807, Fax: (301) 480-0309, ml186r@nih.gov

    See full Notice in NIH Guide:NOT-OD-05-060

  • Supplements for Research on Image-Guided Interventions in SPOREs and Cancer Centers (IGI Supplemental Awards)

    • Release Date: September 06, 2005
    • Application Receipt Date: June 1, 2005
    • Contacts:

      Keyvan Farahani, Ph.D. (farahank@mail.nih.gov) at 301-451-2651

    SUPPLEMENTS FOR RESEARCH ON IMAGE-GUIDED INTERVENTIONS IN SPORES AND CANCER CENTERS (IGI SUPPLEMENTAL AWARDS) (NCI)

    Letter of intent: May 1, 2005

    IGI Supplemental Awards are intended to facilitate the development, validation, and optimization of oncologic IGI methods, as well as the identification of promising, clinically safe and feasible new oncologic IGIs that warrant subsequent multi-center clinical investigations. Collaboration between investigators of the SPORE or Cancer Center and their basic science and engineering colleagues, both within and outside of the institution, and industry when appropriate is encouraged. The inclusion of minorities or individuals from underserved populations as participants in the study and the involvement of a junior clinical investigator in its design and execution are encouraged. Junior investigators with appropriate qualifications are eligible to serve as Principal Investigators. Eligible applicants include all SPORE investigators and Cancer Center investigators, their co-investigators, and clinical and basic scientists in other departments of the institution.

    URL: http://www3.cancer.gov/cancercenters/announcements/IGI_Award.pdf

  • PAR-05-114: Quick-Trials for Imaging and Image-Guided Interventions: Exploratory Grants

    • Release Date: May 20, 2005
    • Application Receipt Date: August 9, December 9, April 9, 2005 through 2008
    • Contacts:

      Lalitha Shankar, M.D., (shankarl@mail.nih.gov) at 301-495-9531
      Keyvan Farahani, Ph.D. (farahank@mail.nih.gov) at 301-451-2651

    The goal of this program is to fund applications focused on the following areas of research: 1) Phase I or II clinical trials of novel imaging-agents to assure their safety and efficacy, so that further evaluations of the clinical potentials of these agents can proceed; 2) Feasibility studies in image-guided intervention, to establish treatment parameters and early therapeutic efficacy for these methods; and/or 3) Clinical feasibility or "proof-of-principle" studies or clinical trials to demonstrate potential efficacy of promising discoveries in imaging or image-guided therapy methodologies or technologies. Investigators may apply for a maximum of 2 years of funding support using the exploratory or developmental (R21) grant mechanism for up to $250,000 direct costs per year. The anticipated number of awards is three to six per year.

    See full description in NIH Guide:PAR-05-114

  • PAR-04-155: Quick Trials for Novel Cancer Therapies: Exploratory Grants

    This PA is intended to provide investigators with rapid access to support for pilot, Phase I, and Phase II cancer clinical trials as well as patient monitoring and laboratory studies. The focus of this QUICK-TRIAL PA is on translational research in new agent or device development to ensure the timely exploitation of new cancer therapeutic. This PA is aimed at providing a new approach in the grant application process by offering a rapid turnaround from application submission to funding. Features of this initiative include a modular grant application and award process, inclusion of the clinical protocol within the grant application, and accelerated peer review with the goal of issuing new awards within six months of application receipt. In addition, QUICK-TRIAL applications do not require extensive preliminary data in the grant application and support exploratory translational and clinical research studies involving cancer prevention, chemotherapy and rapid development and application of novel clinical cancer therapies including image guided therapeutic procedures. Investigators may apply for a maximum of two years of funding support using the exploratory or developmental (R21) grant mechanism for up to $250,000 direct costs per year.

    • Application Receipt Dates: December 9, 2004; April 9, 2005; August 9, 2005; December 9, 2005; April 9, 2006; August 9, 2006; December 9, 2006; April 9, 2007; August 9, 2007; December 9, 2007

    See full description in NIH Guide:PAR-04-155

  • A Service of the National Cancer Institute
  • The Department of Health & Human Services
  • National Institutes of Health
  • National Cancer Institute
  • USA.gov